Regentis Biomaterials Ltd. Achieves Initial Public Offering Success
Herzliya, Israel – Regentis Biomaterials Ltd. (NYSE: RGNT), a pioneering company in regenerative medicine committed to advancing tissue repair solutions, has announced a significant milestone: the completion of its initial public offering (IPO). This strategic move involves 1,250,000 ordinary shares priced at $8.00 each, generating gross proceeds of $10 million before the subtraction of underwriting fees and other associated costs.
Trading Commences for Regentis Ordinary Shares
As of December 4, 2025, the ordinary shares of Regentis began trading on the NYSE American LLC under the stock symbol "RGNT". This marks an exciting new chapter for the company as it strengthens its financial foundation to pursue its mission in the field of regenerative medicine.
Use of Proceeds from the IPO
Regentis intends to allocate the net proceeds from the IPO predominantly towards development activities. Key initiatives include completing its pivotal clinical trials and preparing a Premarket Approval (PMA) submission for its flagship product, GerlinC. Additionally, the funds will assist with corporate necessities, including the repayment of existing debts and deferred compensation obligations.
Partnership with ThinkEquity
ThinkEquity played a crucial role in this IPO, serving as the sole book-running manager. Their expertise significantly contributed to the successful launch of the offering.
Filing with SEC and Compliance Measures
A Registration Statement on Form F-1 concerning the ordinary shares sold in the IPO was filed and became effective on November 12, 2025, with the U.S. Securities and Exchange Commission (SEC). This ensures compliance with regulatory standards and facilitates transparent financial practices. Interested parties can access the final prospectus on the SEC's website, which details all pertinent information regarding the offering.
About Regentis Biomaterials Ltd.
Regentis Biomaterials Ltd. is committed to enhancing patient quality of life through its innovative tissue repair technologies. Focusing on orthopedic solutions, the company utilizes its Gelrin platform, which incorporates degradable hydrogel implants designed to regenerate damaged tissues. Notably, GelrinC, their lead product candidate, offers a unique cell-free hydrogel solution that serves as a temporary implant for treating articular knee cartilage injuries. This product has received a Conformité Européene (CE) mark in Europe and is poised for market commercialization, alongside ongoing FDA approval efforts in the United States.
A Glimpse into GelrinC's Potential
GelrinC operates as a promising therapeutic agent by providing a biocompatible matrix that promotes cartilage healing in patients suffering from knee injuries. As the company ventures into the European market, it looks forward to making a significant impact in regenerative medicine.
Contact Information for Investor Relations
For investor inquiries, individuals can reach out to Arie Gordashnikov. He can be contacted via email at arie@shimony.com or by phone at +972-3-6116629. Regentis continues to prioritize clear communication and transparency with its investors as it embarks on this exciting journey.
Frequently Asked Questions
What is the recent IPO for Regentis Biomaterials Ltd.?
Regentis Biomaterials Ltd. has recently completed its initial public offering, raising $10 million by selling 1,250,000 ordinary shares priced at $8.00 each.
How does Regentis plan to use the proceeds from the IPO?
The company aims to use the proceeds for development activities, including clinical trials for GerlinC, and for corporate purposes like debt repayment.
When did the shares of Regentis start trading?
The ordinary shares of Regentis began trading on December 4, 2025, on the NYSE under the symbol "RGNT".
What is GelrinC and its significance?
GelrinC is Regentis' lead product focusing on treating knee cartilage injuries utilizing a unique hydrogel formula.
Who can I contact for more information regarding investor relations?
For inquiries, you can contact Arie Gordashnikov at +972-3-6116629 or via email at arie@shimony.com.